title: Megestrol acetate in patients with AIDS and cachexia.
abstract: OBJECTIVE
  To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia.
  
  
  METHODS
  Twelve-week, multicenter, randomized, double-blind, placebo-controlled trial.
  
  
  METHODS
  Multiple clinical centers.
  
  
  METHODS
  100 patients with AIDS who had weight loss of 10% or more of ideal body weight were randomly assigned to placebo (n = 48) or megestrol acetate (n = 52).
  
  
  METHODS
  Caloric intake, body weight, body composition, and sense of well-being.
  
  
  RESULTS
  Most patients receiving megestrol acetate had increased caloric intake resulting in body weight gain (mainly fat mass). From baseline to week 8, the megestrol acetate group increased their daily caloric intake by 608 calories, whereas the placebo group increased intake by 134 calories (difference, 474 calories; 95% CI, -68 to 880 calories). Body weight in the megestrol acetate group increased by 3.86 kg from baseline to week 8, although it decreased by 0.46 kg in the placebo group (difference, 4.32 kg; CI, 2.42 to 6.22 kg). At week 8 in the megestrol acetate group, patients gained 3.68 kg in fat mass and those in the placebo group lost 0.28 kg (difference, 3.96 kg; CI, 2.49 to 5.43 kg). Body water, lean mass, and patient survival were not statistically different between treatment groups. Patients treated with megestrol acetate had an increased sense of well-being when compared with patients who received placebo.
  
  
  CONCLUSIONS
  This megestrol acetate liquid formulation is well tolerated, increases food intake, results in body weight gain, and improves the sense of well-being in cachectic patients with AIDS.
authors.affiliation: University of California at Davis.
authors.forename: M H
authors.initials: MH
authors.lastname: Oster
authors.forename: S R
authors.initials: SR
authors.lastname: Enders
authors.forename: S J
authors.initials: SJ
authors.lastname: Samuels
authors.forename: L A
authors.initials: LA
authors.lastname: Cone
authors.forename: T M
authors.initials: TM
authors.lastname: Hooton
authors.forename: H P
authors.initials: HP
authors.lastname: Browder
authors.forename: N M
authors.initials: NM
authors.lastname: Flynn
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000401:mortality; D000328:Adult; D000855:Anorexia / Q000188:drug therapy / Q000209:etiology; D000886:Anthropometry; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D017097:Electric Impedance; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008535:Megestrol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019290:Megestrol Acetate; D008875:Middle Aged; D012649:Self Concept; D016019:Survival Analysis
chemical_list: D008535:Megestrol; D019290:Megestrol Acetate